News & Events

Press Releases

Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

Salarius Announces Allowance of New European Patent Covering Seclidemstat

Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Salarius Pharmaceuticals to Present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference

Events

16th Annual Noble Emerging Growth Investor Conference

Feb 16 - Feb 18

Listen to Webcast

BIO CEO & Investor Conference

Feb 10 - Feb 11

38th Annual J.P. Morgan Healthcare Conference

Jan 13 - Jan 16

Listen to Webcast

Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

Dec 16 @ 8:30 am EST to 7pm EST

https://www.foxchase.org/events/epigenetics-symposium-15-years-lysine-demethylases-discovery-clinic

In the News

Reportable News

Salarius During the JP Morgan Week – Attend the Biotech Showcase Presentation or Join the Live Webcast

Proactive Investors

Salarius Pharmaceuticals CEO talks through recent achievements for its lead cancer drug candidate

Scrip Informa Pharma Intelligence

Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation

Applied Clinical Trials

Emerging Biopharma Find Ways to Persevere Struggles

Salarius CEO, David Arthur discusses the future of the company with SNN Network

Salarius, Aspire Capital announce a $10.9M stock purchase agreement